Orally-active S1P agonist Zeposia (ozanimod) has been submitted to the FDA as a treatment for adults with moderately to severely active ulcerative colitis (UC), with a decision from the US ...

The company is now planning to file for approval later this year, and while it will play catch-up with BMS and Zeposia – which got a green light in UC last year and is also approved for multiple ...

Research revealed that for patients, Ulcerative Colitis (UC) is a life- diminishing condition. For Zeposia's DTC launch, the category is dominated by high-spending competitors and long-ingrained ...